Home > Boards > US Listed > Biotechs > Affimed Therapeutics (AFMD)

If this thing has so much going for

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Lynx5100 Member Profile
 
Followed By 2
Posts 146
Boards Moderated 0
Alias Born 03/17/14
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/14/2021 5:16:43 PM
Affimed Announces Pricing of $100,000,000 Public Offering of Common Shares GlobeNewswire Inc. - 1/13/2021 6:15:00 AM
Affimed Announces Proposed Public Offering of Common Shares GlobeNewswire Inc. - 1/12/2021 4:01:00 PM
Affimed to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/11/2021 6:45:00 AM
Affimed Announces €25 Million Debt Financing Agreement with Silicon Valley Bank GlobeNewswire Inc. - 1/11/2021 6:30:00 AM
Affimed Announces Pipeline and Business Update GlobeNewswire Inc. - 1/7/2021 6:30:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/18/2020 4:14:43 PM
Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstratin... GlobeNewswire Inc. - 12/7/2020 10:01:00 AM
Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s a... GlobeNewswire Inc. - 11/19/2020 4:01:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/10/2020 8:22:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/10/2020 8:15:33 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/10/2020 6:34:41 AM
Affimed Reports Third Quarter 2020 Financial Results and Highlights Recent Operational Progress GlobeNewswire Inc. - 11/10/2020 6:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/9/2020 4:32:37 PM
Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Inna... GlobeNewswire Inc. - 11/9/2020 4:01:00 PM
New Preclinical Data being Presented at SITC Underscore Promising Combinations of Affimed’s AFM13 and Cytokine-Activated Na... GlobeNewswire Inc. - 11/9/2020 8:20:00 AM
Artiva Biotherapeutics and Affimed Announce Platform-to-Platform R&D Collaboration for Targeted Off-the-Shelf NK Cell Therapi... GlobeNewswire Inc. - 11/5/2020 4:01:00 PM
Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting an... GlobeNewswire Inc. - 11/4/2020 4:05:00 PM
Affimed to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 11/4/2020 6:30:00 AM
Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020 GlobeNewswire Inc. - 11/3/2020 6:30:00 AM
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer ... GlobeNewswire Inc. - 10/20/2020 6:30:10 AM
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer ... GlobeNewswire Inc. - 10/20/2020 6:30:00 AM
Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for I... GlobeNewswire Inc. - 10/14/2020 5:15:00 PM
Affimed Announces Dosing of First Patient in Phase 1 Clinical Trial of Cord Blood-derived Natural Killer Cells in Combination... GlobeNewswire Inc. - 10/6/2020 6:30:00 AM
AbCheck s.r.o. Receives Grant to Further Develop a Discovery Technology for Functional Antibodies using Microfluidics GlobeNewswire Inc. - 10/6/2020 6:30:00 AM
Lynx5100   Tuesday, 07/14/20 10:47:57 AM
Re: MWM post# 207
Post # of 237 
If this thing has so much going for it why the selling

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences




Ticker News is disabled